Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.78% | -0.90% | -0.50% | -5.30% | -23.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.41% | 46.32% | 18.38% | -33.55% | -45.94% |
| Operating Income | 4.41% | -46.32% | -18.38% | 33.55% | 45.94% |
| Income Before Tax | -25.56% | -58.07% | -31.35% | 25.94% | 35.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.56% | -58.07% | -31.35% | 25.94% | 35.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.56% | -58.07% | -31.35% | 25.94% | 35.51% |
| EBIT | 4.41% | -46.32% | -18.38% | 33.55% | 45.94% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.35% | -27.67% | -7.26% | 31.81% | 39.02% |
| Normalized Basic EPS | 1.12% | -27.85% | -6.32% | 32.11% | 38.91% |
| EPS Diluted | 0.35% | -27.67% | -7.26% | 31.81% | 39.02% |
| Normalized Diluted EPS | 1.12% | -27.85% | -6.32% | 32.11% | 38.91% |
| Average Basic Shares Outstanding | 25.55% | 21.36% | 18.41% | 11.10% | 6.73% |
| Average Diluted Shares Outstanding | 25.55% | 21.36% | 18.41% | 11.10% | 6.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |